insight addit chronic cough expert continu
support select antagonist approach
continu dilig bellu health toronto blu spoke two addit lead
chronic cough expert bring number extern expert consult notabl
larg major kol spoke optimist antagonist class believ
select agent develop bellu bayer xetra bayn de least close
effect merck nyse gefapix without associ tast effect
potenti interest mechan develop refractory/idiopath chronic cough
 agonist nachr antagonist advanc demonstr
anti-tuss benefit clinic addit convers reveal market
antagonist could stretch beyond refractory/idiopath chronic cough note patient
asthma copd ipf could also benefit treatment note model
account popul
insight convers email us detail note convers
remind recent initi coverag bellu copi report found
convers kol kol clinic pulmonologist uk work
cough space year develop mani tool use measur
outcom cough led multipl clinic trial refractory/idiopath chronic cough
done lot work antagonist space insight includ
kol believ refractory/idiopath chronic cough commonli mislabel
physician today antituss agent approv physician educ
neuropath condit kol note chronic cougher may consid
refractory/idiopath higher current estim patient estim chronic
cough year
kol optimist antagonist class whole believ
effect refractory/idiopath chronic cough popul also
expect select asset develop bayer bellu effect
gefapix without associ tast effect howev without data unsur
whether improv effect tast compar bayer asset
better idea ye expect see result bayer
program given tast effect phase studi bellu highli select agent
select tast effect increas higher dose expect
tast effect bayer agent pronounc select
kol note util anti-tuss agent may driven price
negoti payor
kol interest nicotin agonist asset develop emphas
littl human data either drug class time
kol believ market antagonist much larger refractory/
idiopath patient popul addit acut cough kol think potenti
address sever cough asthma copd idiopath pulmonari fibrosi ipf
patient well
mid begin phase ii studi chronic cough
mid phase ii result chronic cough
year left
short interest float
financi cad
analyst certif disclosur pleas see page
convers kol kol clinic pulmonologist run one largest us cough center patient involv
mani cough program develop takeaway convers follow
us alon annual visit healthcar provid cough way determin percentag
patient chronic cougher specifi bill code diseas kol believ preval refractory/
idiopath cough rang gener popul model assum preval
kol believ mechanist rational behind antagonist look forward see result select agent
bayer bellu approv note everi one patient would candid antagonist
kol note guinea pig model good research tool human share mani cough trigger howev anti-tuss
efficaci result directli correl guinea pig human demonstr mani failur
kol excit receptor antagonist class privat run larger better phase iib
trial menlo result encourag orvepit demonstr decreas cough
frequenc open-label studi compar placebo gefapix phase iib studi remind data
expect
clinic data avail yet kol optimist attenua bradaniclin note peripherally-act anti-tuss agent
effect inhibit cough specif trigger antagonist work patient base gefapix data wherea
centrally-act asset like nicotin agonist theoret potenti suppress cough irrespect trigger data attenua
poc phase ii studi expect ye note expert potenti bia heavili involv attenua start also
magnitud cough suppress could differ antagonist agonist nachr better idea data
kol believ antagonist also clinic effect acut cough think merck recent phase ii failur merck
recent termin trial could due trial design rather drug class expert mention healthi individu infect
viru may cough enough elicit statist respons wide rang cough sever patient ultim better
detail previou kol convers includ includ initi
twelve-month price target base dcf valuat assum wacc termin growth rate million fulli
potenti upsid model includ better expect clinic result could requir us boost peak penetr
probabl success relev indic expans addit indic potenti success earlier
anticip regulatori approv sale surpass expect patent extens
risk price target includ wors expect clinic result unforeseen competit emerg
initi target indic chang regulatori environ market downturn potenti dilut financ
alpha seri
lifesci capit alpha seri intend encompass high conviction/impact idea within healthcar sector analys
recommend base deep fundament analysi goal help creat alpha investor long run
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect secur subject
compani research analyst cover research view express report accur reflect person view
subject secur subject compani part research analyst compens directli
indirectli relat specif recommend view express research analyst report
